Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A et al (2022) Breast cancer statistics. CA 72(6):524–541

PubMed  Google Scholar 

Knape N, Park JH, Agala CB, Spanheimer P, Morrow M, Downs-Canner S et al (2023) Can we forgo sentinel lymph node biopsy in women aged ≥ 50 years with early-stage hormone-receptor-positive HER2-negative special histologic subtype breast cancer? Ann Surg Oncol 30(2):1042–1050. https://doi.org/10.1245/s10434-022-12626-6

Article  PubMed  Google Scholar 

Burguin A, Diorio C, Durocher F (2021) Breast cancer treatments: updates and new challenges. J Pers Med 11(8):808. https://doi.org/10.3390/jpm11080808

Article  PubMed  PubMed Central  Google Scholar 

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al (2017) Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131. https://doi.org/10.1056/NEJMoa1703643

Article  Google Scholar 

Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752. https://doi.org/10.1200/jco.2014.55.5730

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fehrenbacher L, Cecchini RS, Geyer CE Jr, Rastogi P, Costantino JP, Atkins JN et al (2020) NSABP B-47/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol 38(5):444–453. https://doi.org/10.1200/jco.19.01455

Article  CAS  PubMed  Google Scholar 

Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA et al (2010) Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(7):1131–1137. https://doi.org/10.1200/jco.2009.24.1661

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou S, Liu T, Kuang X, Zhen T, Shi H, Lin Y et al (2022) Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer. Breast 67:1–7. https://doi.org/10.1016/j.breast.2022.12.006

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Abudureheiyimu N, Mo H, Guan X, Lin S, Wang Z et al (2021) In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: a study of the national cancer center. China Front Oncol 11:774577. https://doi.org/10.3389/fonc.2021.774577

Article  CAS  PubMed  Google Scholar 

Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B et al (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7(1):1. https://doi.org/10.1038/s41523-020-00208-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K et al (2020) Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382(7):610–621. https://doi.org/10.1056/NEJMoa1914510

Article  CAS  PubMed  Google Scholar 

Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J et al (2020) Antitumor activity and safety of Trastuzumab Deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol 38(17):1887–1896. https://doi.org/10.1200/jco.19.02318

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9–20. https://doi.org/10.1056/NEJMoa2203690

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V et al (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20(8):1124–1135. https://doi.org/10.1016/s1470-2045(19)30328-6

Article  CAS  PubMed  Google Scholar 

Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M et al (2021) Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 22(8):1151–1161. https://doi.org/10.1016/s1470-2045(21)00301-6

Article  CAS  PubMed  Google Scholar 

Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J et al (2022) Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol 8(8):1177–1183. https://doi.org/10.1001/jamaoncol.2022.2286

Article  PubMed  PubMed Central  Google Scholar 

Kang S, Lee SH, Lee HJ, Jeong H, Jeong JH, Kim JE et al (2022) Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. Eur J Cancer 176:30–40. https://doi.org/10.1016/j.ejca.2022.08.031

Article  CAS  PubMed  Google Scholar 

Alves FR, Gil L, Vasconcelos de Matos L, Baleiras A, Vasques C, Neves MT et al (2022) Impact of Human Epidermal Growth Factor Receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer. Cureus 14(2):e22330. https://doi.org/10.7759/cureus.22330

Article  PubMed  PubMed Central  Google Scholar 

de Moura LL, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimarães PT et al (2021) HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat 190(1):155–163. https://doi.org/10.1007/s10549-021-06365-7

Article  CAS  Google Scholar 

Shao Y, Yu Y, Luo Z, Guan H, Zhu F, He Y et al (2022) Clinical, pathological complete response, and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting: a retrospective analysis. Ann Surg Oncol 29(13):8026–8034. https://doi.org/10.1245/s10434-022-12369-4

Article  PubMed  Google Scholar 

Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM et al (2023) Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol 41(22):3867–3872. https://doi.org/10.1200/jco.22.02864

Article  CAS  PubMed  Google Scholar 

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093

Article  CAS  PubMed  Google Scholar 

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874. https://doi.org/10.1073/pnas.191367098

Article  PubMed  PubMed Central  Google Scholar 

Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20):3271–3277. https://doi.org/10.1200/jco.2009.25.9820

Article  PubMed  Google Scholar 

Mallin K, Browner A, Palis B, Gay G, McCabe R, Nogueira L et al (2019) Incident cases captured in the national cancer database compared with those in U.S. Population Based Central Cancer Registries in 2012–2014. Ann Surg Oncol 26(6):1604–1612. https://doi.org/10.1245/s10434-019-07213-1

Article  PubMed  Google Scholar 

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235. https://doi.org/10.1007/s10549-006-9242-8

Article  PubMed  Google Scholar 

Plichta JK, Rushing CN, Lewis HC, Rooney MM, Blazer DG, Thomas SM et al (2023) Implications of missing data on reported breast cancer mortality. Breast Cancer Res Treat 197(1):177–187. https://doi.org/10.1007/s10549-022-06764-4

Article  PubMed  Google Scholar 

Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG et al (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338:b2393. https://doi.org/10.1136/bmj.b2393

Article  PubMed  PubMed Central  Google Scholar 

White IR, Royston P, Wood AM (2011) Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30(4):377–399. https://doi.org/10.1002/sim.4067

Article  PubMed  Google Scholar 

Rubin DB (1996) Multiple imputation after 18+ years. J Am Stat Assoc 91(434):473–489

Article  Google Scholar 

VanderWeele TJ, Ding P (2017) Sensitivity analysis in observational research: introducing the E-Value. Ann Intern Med 167(4):268–274. https://doi.org/10.7326/m16-2607

Article  PubMed  Google Scholar 

Haneuse S, VanderWeele TJ, Arterburn D (2019) Using the E-Value to assess the potential effect of unmeasured confounding in observational studies. JAMA 321(6):602–603. https://doi.org/10.1001/jama.2018.21554

Article  PubMed  Google Scholar 

Li JJ, Yu Y, Ge J (2023) HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. Breast Cancer. https://doi.org/10.1007/s12282-022-01431-4

Article  PubMed  PubMed Central